摘要
目的采用meta分析法对复方鳖甲软肝片治疗乙型肝炎的论文进行分析。方法纳入"以慢性乙型肝炎或乙型肝炎肝硬化为研究对象,对照组口服核苷类药物抗病毒治疗,试验组加用复方鳖甲软肝片治疗"的临床随机试验,使用Revman软件对治疗前后血清纤维化标志物的变化进行meta分析。结果在521篇发表论文中析出符合要求的论文8篇;Meta分析提示,在治疗12个月后,与对照组比,复方鳖甲软肝片治疗患者血清透明质酸、层粘连蛋白、Ⅲ型前胶原和IV型胶原的降低程度均显著优于对照组,其对应的权重均数差及95%可信区间分别为80.62μg/L[-127.77-33.47],52.02μg/L[-81.60-22.45],72.26μg/L[-109.6-34.92],53.84μg/L[-91.65-16.03],上述P值均小于0.05。结论复方鳖甲软肝片治疗乙型肝炎患者能够有效降低血清纤维化标志物。
Objective To investigate the effect of FuFang BieJia RuanGan Pian on serum fibrotic markers by meta analysis. Methods Literatures involving FuFang BieJia RuanGan Pian in treatment of patients with hepatitis B and liver cirrhosis were retrieved. The patients in control group receiving nucleoside analogs and patients in experimental group receiving combination FuFang BieJia RuanGan Pian and anti-viral agents. Software of Revman was used for statistical analysis of the fibrostic indexe changes. Results Out of 521 papers,8 were selected. Meta analysis showed that after 12 month treatment,the serum fibrotic markers in experimental group decreased with the weight mean differences and 95% confidence interval for hyaluronie acid,laminin,precollagen type mand collagen type IV were 80.62μg/L[-127.77-33.47],52.02μg/L[-81.60-22.45],72.26μg/L[-109.6,-34.92], and 53.84μg/L [-91.65,-16.03],respectively （P〈0.05）. Conclusion FuFang BieJia RuanGan Pian can decrease serum fibrotic markers in patients with chronic hepatitis B viral infection.
出处
《实用肝脏病杂志》
CAS
2012年第6期524-526,共3页
Journal of Practical Hepatology
